• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • 0 CME Hours
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
#Grand Rounds

Can Valaciclovir Prevent Vertical Transmission of CMV?

image_pdfFavoriteLoadingFavorite

PURPOSE:

  • Valaciclovir has been used in pregnancy to treat herpes simplex infections
  • Shahar-Nissan et al. (Lancet, 2020) sought to determine if valaciclovir administered to pregnant women with a primary cytomegalovirus infection is effective in preventing vertical transmission of cytomegalovirus (CMV)

METHODS:

  • Prospective, randomized, double-blind, placebo-controlled trial
  • Participants
    • Pregnant women ≥18 years
    • Primary CMV based on serologic evidence | Acquired periconceptionally or first trimester
    • Opted for amniocentesis to confirm diagnosis
  • Randomized to one of two groups from enrolment until amniocentesis at 21 or 22 gestational weeks
    • Oral valaciclovir: 8 g per day, twice daily
    • Placebo
  • CMV testing done on amniocentesis specimens
    • If patients declined amniocentesis, CMV positive infants assumed to be positive at time of amnio and CMV infants assumed to be negative
  • Sample size of 38 for each group
    • Detect reduction in CMV transmission from 40% in the placebo group to 10% in the valaciclovir group
    • 80% power by two-sided test at a 5% significance level
  • Primary outcome
    • Rate of vertical CMV transmission

RESULTS:

  • 45 patients in the valaciclovir group (singletons) | 45 patients in placebo group (43 singletons and two sets of twins)
  • First trimester and periconceptional infections combined (positive CMV detected in amniocentesis specimens)
    • Rate of vertical transmission was lower in the valaciclovir group (p=0.027)
      • Valaciclovir: 11%
      • Placebo: 30%
      • Odds ratio (OR) 0·29 (95% CI, 0.09 to 0.90)
  • First trimester infection (positive CMV detected in amniocentesis specimens)
    • Rate of vertical transmission was lower in the valaciclovir group (p=0.020)
      • Valaciclovir group: 11%
      • Placebo: 48%  
  • Post-hoc analysis to exclude patients who declined amnio
    • Effect of valacyclovir on vertical transmission reduction remained (p=0.038)
  • No adverse effects were observed

CONCLUSION:

  • Valaciclovir appears to reduce vertical transmission of CMV in women who acquired the infection early in pregnancy
  • The authors state that

Combined with appropriate screening and further strengthening in larger trials, this strategy might safely and effectively alleviate neonatal short and long-term cytomegalovirus-related morbidity 

Learn More – Primary Sources:

Valaciclovir to prevent vertical transmission of cytomegalovirus after maternal primary infection during pregnancy: a randomised, double-blind, placebo-controlled trial

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone, with ObGFirst

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All #Grand Rounds Posts
Next >

Related ObG Topics:

SMFM Recommendations: FGR Diagnosis and Management
Practical obstetrics info for your women's healthcare practice
Second Trimester Echogenic Bowel: Important Ultrasound Finding with Varied Causes and Some Serious Implications
What Percentage of Stillbirths are Caused by Infection?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • #Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

ObG Library

  • Hysteroscopy
  • Fertility
  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Log In to ObG First

Please log in to access OBGFirst and the 2T Ultrasound Atlas

Password Trouble?

Sign Up for ObGFirst

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!

ObG First Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site